Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Cooper Investors Global Equities Fund (Unhedged) Cooper Investors Pty Limited | “As businesses with unique and uncorrelated return drivers, Daikin and Corteva complement our existing Reversionary investments, such as pharmaceutical glass manufacturer Stevanato (STVN” | BULL | Q2 2026 Jul 31, 2026 | View Pitch |
Riverwater Partners Small Cap Strategy Nathan Fredrick, CFA | “In addition, we initiated positions in Stevanato Group (STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. The stock sold off following the launch of oral GLP-1s, which many believe will end the need for injectable forms. Experts believe an expanding GLP-1 TAM, coupled with varying use cases, will necessitate ongoing need for injectable forms. Indeed, 25% of drugs approved in 2025 were biologics which will require injectable devices. This market overreaction offered an attractive entry valuation of 12.5x FY2026E EBITDA vs. STVN's historic multiple of 20X and its nearest comp West Pharmaceutical (WST) at approximately 22–25x.” | NEUTRAL | Q2 2026 Jul 17, 2026 | View Pitch |
Riverwater Sustainable Value Strategy Adam J. Peck, CFA | “Founded in 1949 and headquartered in Piombino Dese, Italy, Stevanato is a leading global provider of drug containment and delivery solutions (think glass vials and syringes) to the pharmaceutical, biotechnology, and life sciences industries. The company remains family controlled, with Franco Stevanato serving as CEO and Board Chair and the family owning 78% of the stock, aligning its interests with ours. After monitoring the company for several years, our recent discussions with management reinforced our confidence in the franchise's durability. Stevanato has evolved from a regional glass manufacturer into a vertically integrated, mission critical supplier serving customers in more than 70 countries. Regulatory qualification of its manufacturing processes creates significant switching costs. STVN made a strategic shift to focus its new capacity on High-Value Solutions (HVS), which include premium products such as Nexa® high-performance prefilled syringes and EZ-fill® vials and cartridges designed for biologics and sensitive drug formulations. These intentional moves have enabled an inflection in revenue growth, margin expansion, and free cash flow generation. The stock sold off after the launch of oral GLP-1 drugs, which some believe will end the need for injectable formats. We disagree and believe that an expanding GLP-1 market with varied use cases should sustain injectable demand. Indeed, 25% of drugs approved in 2025 were biologics which will require injectable devices. The overreaction gave us an opportunity to buy at 12.5x expected fiscal 2026 EBITDA versus the company's historic 20x and its closest comparable, West Pharmaceutical (WST), at 22x to 25x.” | BULL | Q2 2026 Jul 17, 2026 | View Pitch |
Conestoga Small Cap Composite Joe Monahan | “STVN provides drug containment and delivery solutions to pharmaceutical and biotechnology companies. The stock struggled as investors weighed solid results against a mixed underlying business mix and ” | BULL | Q1 2026 Mar 31, 2026 | View Pitch |
Artisan Partners Small Cap Fund Jay Warner | “Stevanato is a leading provider of specialty glass and plastic packaging to the health care industry, as well as the leading machinery supplier to glass vial makers and fill and finish facilities. The stock was weak this quarter as the market tried to sort out the implications of Eli Lilly's pending launch of an oral GLP-1, Orforglipron, for Stevanato's profit cycle with respect to its vial and syringe production. We remain invested in the stock as we believe not only in the continued penetration of GLP-1 in liquid form, where titration benefits remain, but more importantly in the future increases in liquid-based biological drugs. Additionally, Medicare- and Medicaid-based coverage of GLP-1s should increase overall drug volume, regardless of average selling price pressures on GLP-1 manufacturers themselves. BSD Analysis: Stevanato sits at a quiet choke point in global pharmaceuticals by supplying drug containment systems that regulators and manufacturers cannot compromise on. Vials, syringes, and cartridges look commoditized until contamination risk makes switching suppliers unthinkable. COVID distorted demand optics, but biologics and injectables keep expanding structurally. High validation and qualification requirements create brutal switching costs. Investors fixate on volume normalization and miss long-cycle embedment. Capacity investments depress near-term returns but extend relevance for years. Margins reflect process control and quality, not glass pricing. This is healthcare infrastructure hiding inside packaging. Boring containers, existential importance.” | BULL | Q4 2025 Jan 21, 2026 | View Pitch |
Alger Small Cap Focus Fund Amy Zhang | “Stevanato is a leading supplier of pharmaceutical-grade glass packaging used to store and deliver medicines, including vials, pre-filled syringes, and cartridges. The company also provides end-to-end solutions that support the drug life cycle, which can shorten lead times, lower total costs, and reduce supply-chain risk for customers. Shares detracted in the fourth quarter after third-quarter results benefited from shipment timing, with orders pulled forward into Q3, raising concerns that fourth-quarter results would be softer. Full-year revenue guidance was unchanged, implying a fourth-quarter outlook slightly below expectations. In addition, some investors remain concerned that the growth of oral GLP-1 drugs could eventually take share from injectable GLP-1s, a recent demand driver for Stevanato's delivery components. BSD Analysis: Stevanato supplies critical drug-containment and delivery solutions, including glass vials and prefillable syringes, to global pharma customers. Its products are embedded in regulatory workflows, creating high switching costs. Demand is driven by biologics growth and injectable drug pipelines. Margins are attractive due to technical complexity and long-term contracts. Capital intensity is meaningful, but returns scale with volume. Cyclicality is limited because pharma production doesn't stop. Stevanato is a quiet life-sciences infrastructure compounder.” | BULL | Q4 2025 Jan 8, 2026 | View Pitch |
Conestoga SMid Cap Composite Derek Johnston | “STVN underperformed as its engineering segment reported a 20% revenue decline, weighing on overall results. Although the segment represents a smaller portion of revenue, the slower-than-expected turnaround pressured sentiment. Investor concerns also increased around the potential impact of oral GLP-1 therapies on injectable drug demand. Near-term uncertainty overshadowed otherwise solid core demand. BSD Analysis: Stevanato supplies drug containment solutions essential to injectable pharmaceuticals. Demand is driven by biologics and self-administration trends. COVID normalization hurt optics but not relevance. Regulatory validation creates brutal switching costs. Margins reflect process control, not commodity glass. Investors overreact to volume normalization. Capacity investments position Stevanato for pipeline growth. This is healthcare infrastructure hiding in vials. Boring, essential, sticky.” | BEAR | Q4 2025 Dec 31, 2025 | View Pitch |
Artisan Partners Small Cap Fund Jay Warner | “Stevanato is a leading provider of specialty glass and plastic packaging to the health care industry, as well as the leading machinery supplier to glass vial makers and fill and finish facilities. We believe a mix shift from bulk products to higher margin sterilized products and the overall growth of biologic drugs will drive attractive earnings growth. We increased our position as we gained greater confidence that the worst of the COVID-related inventory overstocking challenges had passed. Moving forward, we believe the company's and industry's profit cycle drivers are more likely to demonstrate the durable growth characteristics that originally attracted us to this stock. BSD Analysis: Stevanato stands to benefit from structural growth in biologics and a mix shift toward high-margin sterile packaging, supporting multi-year EBITDA expansion. Inventory normalization removes a key overhang, and valuation remains attractive versus global life-science tools peers. Key risks include customer concentration and regulatory delays.” | BULL | Q2 2025 Jul 22, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
